Access to POEMs and Essential Evidence Plus will no longer be included in CMA membership as of Dec. 1, 2023.
Clinical Question
Is pharmacogenomic-guided antidepressant treatment beneficial in the management of adults with major depressive disorder?
Bottom line
As expected, pharmacogenomic testing for drug-gene interactions for adults with MDD resulted in reduced prescribing of medications with potential drug-gene interactions. However, no significant difference occurred in symptom remission rates in the gene-tested group compared with the usual care group at 6 months. 1b
Reference
Study design: Randomized controlled trial (single-blinded)
Funding: Industry + foundation
Setting: Outpatient (any)
Synopsis
The benefit of pharmacogenomic-guided selection of antidepressant therapy remains uncertain on the basis of low-quality evidence to date. These investigators identified adults, aged 18 to 80 years, who met standard diagnostic criteria for major depressive disorder (MDD), had a history of at least 1 prior treatment episode, and had a clinician who was planning to either switch treatment or start a new treatment episode. All patients (N = 1944) underwent DNA collection and were then randomly assigned (concealed allocation) to either a group whose clinicians received the pharmacogenomic test results within 3 business days or a group whose clinicians had to wait 24 weeks for results. Clinicians in the pharmacogenomic-guided group initiated treatment based on the results; the clinicians in the delayed-results group initiated treatment as usual. Individuals masked to treatment group assignment assessed the treatment results using standard scoring tools at 4, 8, 12, 18, and 24 weeks. Complete follow-up occurred for 79% of patients at 24 months. Using intention-to-treat analysis, as expected, the pharmacogenomic-guided group was significantly more likely to receive treatment with an antidepressant with no potential drug-gene interaction. Remission rates were significantly increased in the gene-guided group at 8 and 12 weeks, but not at 4, 18, or 24 weeks. The authors note that there were multiple comparisons made without statistical corrections, so any results beyond the primary outcome of drug choice and remission at 24 weeks are subject to "fishing expedition" significance.
Reviewer
David C. Slawson, MD
Professor and Vice Chair of Family Medicine for Education and Scholarship
Atrium Health
Professor of Family Medicine, UNC Chapel Hill
Charlotte, NC
Comments
Antidepressants
There's no magic way to predict response to specific antidepressants.
PHARMACOGENETIC TESTING FOR GENE INTERACTION AND CHOICE OF A
NO BETTER THAN REGULAR RX